Factory Supply High Quality Anti-Cancer API ABT-199 Venetoclax CAS 1257044-40-8

Product Description:

Product Name	ABT-199
CAS No.	1257044-40-8
Appearance	Yellow Powder

ABT-199 is a novel anti-cancer drug, a Bcl-2 inhibitor, developed by the American pharmaceutical company AbbVie. It can effectively resist cancer and has fewer side effects compared to current drugs. This study was mainly conducted by researchers from the United States and Australia, and the related research results were published in the international journal Nature Medicine.
Unlike ordinary cancer drugs, this drug named ABT-199 works by attacking an important protein called BCL-2 to treat cancer. BCL-2 is one of the earliest discovered members of the BCL-2 protein family that regulates cell death. It is associated with many types of cancer, as well as some mental illnesses and autoimmune diseases. In cancer, it is believed to act as an inhibitor that can help cancer cells resist cancer treatment drugs.
In the treatment of cancer, cancer cells can utilize the survival promoting protein BCL-2 to suppress the therapeutic effect of traditional chemotherapy, which often causes headaches for clinical doctors. It is precisely because cancer cells can use the survival promoting protein BCL-2 to suppress the therapeutic effect of traditional chemotherapy that clinical treatment doctors have to repeatedly increase the dosage, leading to chemotherapy side effects such as nausea and hair loss.
The emergence of ABT-199 as a drug that can eliminate and reduce BCL-2 in cancer cells has shown many clinical doctors the dawn of cancer treatment. ABT-199, as a novel anti-cancer drug, can inhibit the growth of BCL-2 without affecting BCL-XL, a protein essential for platelet formation. The overcoming of this problem is definitely worth celebrating in the history of cancer treatment.
[Clinical Trial Evaluation]: The Phase I clinical trial (NCT01328626) enrolled 84 patients with relapsed/refractory CLL/SLL and 44 patients with relapsed/refractory non Hodgkin lymphoma. The response rate of ABT-199 treatment for CLL/SLL was 79% (complete response rate was 22%), and the median duration of response was 20.5 months; The response rate of ABT-199 treatment for non Hodgkin lymphoma is 48% (complete response rate is 7.5%). The efficacy of ABT-199 can rival that of obinutuzumab, idelalisib, and ibrutinib, and is expected to become the first Bcl-2 inhibitor to be marketed.

FAQ:

1. What's the MOQ?

Generally the MOQ is 1kg, Best 25KG/DRUM

1. Is there any discount?

Yes, we will give you the best discount according to the size of your order!

1. How can I confirm the product quality before placing orders?

We will send you the existing sample or prepare the sample according to your request and send it to you for your confirmation!

1. How do you treat quality complaint?

If the quality problem is confirmed to be caused by us, we will replace the goods or refund your payment immediately!

1. How to contact with us ?

Through SKYPE, WHATSAPP, WeChat, and E-mail.

1. How to place an order & payment ?

(1). Conduct product consultation,
(2). Determine the sample,
(3).After the sample quality meets the requirements, send us the PO,
(4). We reply to PI
(5). The customer completes the payment,
(6). Receive payment for goods, export products,
(7). The customer receives the goods and completes the order.

Cooperative customers:
Our products are exported to European and American countries.
It also has a large customer base in Southeast Asia and other regions.

After-sale service:
If the quality problem is confirmed to be caused by us, we will replace the goods or refund your payment immediately!
100% responsible person, safe and reliable, integrity first.